



بسم الله الرحمن الرحيم

∞∞∞∞

تم رفع هذه الرسالة بواسطة / سامية زكى يوسف

بقسم التوثيق الإلكتروني بمركز الشبكات وتكنولوجيا المعلومات دون أدنى

مسئولية عن محتوى هذه الرسالة.

ملاحظات: لا يوجد



Antidepressant effect of saxagliptin in an experimental model of depression in rats: Role of incretin

Thesis

Presented for the partial fulfillment of

**Master Degree in Pharmaceutical Sciences
(Pharmacology & Toxicology)**

By

MennatAllah Nazeem Mostafa Hassan

Bachelor of Pharmaceutical Sciences 2016, Faculty of Pharmacy, Ain Shams University

Quality control specialist

Egyptian Drug Authority (EDA) (formerly NODCAR)

Under the Supervision of

Dr. Reem Nabil Abou El-Naga

Associate professor of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University

Dr. Amany Mohammed Ahmed Gad

**Associate professor of Pharmacology and Toxicology, Faculty of Pharmacy, Sinai University, East Kantara Branch, New city, El Esmailia
Egyptian Drug Authority (EDA) (formerly NODCAR)**

Dr. Sara Abdel Moneim Wahdan

Associate professor of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University

Faculty of Pharmacy - Ain Shams University

2022

ACKNOWLEDGEMENT

All thanks and gratitude is to my lord Allah, who has given me the strength and will to finish this work. Words and thanks will never suffice to praise Allah for his mercy, blessings and guidance that lead me through the tough times.

I would like to express my deepest gratitude and sincere appreciation to ***Dr. Reem Nabil Abou El-Naga***, Associate professor of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, for her kind and expert supervision, patience, unlimited support, generous assistance, and for the extensive effort, time and energy. All credit goes to her for participating in choosing the thesis point from the department search line. I am heavily indebted to her tremendous efforts, deep experience, the valuable time, and generous assistance during all stages of this study.

My profound thanks are to ***Dr. Amany Mohammed Ahmed Gad***, Associate professor of Pharmacology and Toxicology, Faculty of Pharmacy, Sinai University, East Kantara Branch, New city, El Esmailia, who was always supporting me with great patience, constructive advice and valuable assistance throughout the whole work and for actively supervising the experimental work steps and solving the daily problems. I will always be indebted to her kindness and continuous encouragement. No words can describe my gratitude to her. It's really an honor to be one of her students. She embraced this thesis with useful comments, and valuable time that she sacrificed for me during this work, without which I would have never been able to produce such a work.

My sincere appreciation to ***Dr. Sara Abdel Moneim Wahdan***, Associate professor of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, for her supervision, untiring help, valuable assistance, priceless guidance and fruitful opinions throughout the whole practical work which made her a backbone of this research. The supervision and support that she gave me truly helped the progression and smoothness of this work.

I am very grateful to my dear parents, may Allah give them health and wellness, dear brother, dear daughter and especially my dear husband for standing by me in every step, for their praying, their continuous support and encouragement all the way through and giving me all the strength and faith more than I needed.

Finally my sincere appreciation and thanks go to all my colleagues in National Organization for Drug Control & Research (NODCAR), for their friendly cooperation and constant support.

MennatAllah Nazeem Mostafa

قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا إِلَّا مَا
عَلَّمْتَنَا إِنَّكَ أَنْتَ الْعَلِيمُ الْحَكِيمُ

سورة البقرة آية (32)

Contents

Subject

.....

Page No.

List of Abbreviations	I
List of Tables	IV
List of figures	V
Review of literature	1
<i>1. Depression</i>	1
<i>2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors</i>	29
<i>3. Saxagliptin</i>	32
Aim of the work	39
Material and Methods	40
Results	104
Discussion	144
Summary and conclusion	150
Graphical Abstract	157
References	158
الملخص العربي	أ

List of abbreviations

List of abbreviations

5-HT	Serotonin/5-hydroxytryptamine
p-AKT	phosphorylated-Protein kinase B
ATP	Adenosine triphosphate
AST	Aspartate aminotransferase
ALT	Alanine transaminase
ASC	Apoptosis-associated speck-like protein containing a caspase recruitment domain
ABC-HRP	Avidin-Biotin-Peroxidase Complex
BD	Bipolar Disease
BDNF	Brain-derived neurotrophic factor
BSA	Bovine Serum Albumin
cAMP	Cyclic adenosine monophosphate
CYP	Cytochrome P450
Cu ⁺²	Copper ion
CK	Creatine kinase
CK-MB	Creatine kinase-MB
CUMS	Chronic unpredictable mild stress
DMSO	Dimethyl sulphoxide
DPP-4	Dipeptidyl peptidase-4
DNA	Deoxyribonucleic acid
DOCA	Deoxycorticosterone acetate
DTNB	5,5 dithiobis(2-nitrobenzoic acid)
EDTA	Ethylenediaminetetraacetic acid
ELISA	Enzyme-linked immunosorbent assay
FST	Forced swimming test
FLX	Fluoxetine
Fe ⁺³	Ferric ion
GSH	Glutathione
GIP	Glucose-dependent insulintropic peptide
GLP-1	Glucagon like peptide-1
GSK-3B	Glycogen synthase kinase-3B
GPCR	G-protein-coupled receptors
GGT	Gamma-glutamyl transferase

List of abbreviations

H&E	Hematoxylin & Eosin
HCl	Hydrochloric acid
HPA	Hypothalamic–pituitary–adrenal
HRP	Horseradish Peroxidase
IL-1 β	Interleukin-1 β
IL-6	Interleukin-6
iNOS	Inducible nitric oxide synthase
LH	Learned helplessness
LDL	Low-density lipoproteins
MAO	Monoamine oxidase
MAOIs	Monoamine Oxidase Inhibitors
MDA	Malondialdehyde
MDD	Major depressive disorder
mRNA	Messenger ribonucleic acid
MRI	Magnetic resonance imaging
MAPK	Mitogen-activated protein kinase
MnSOD	Manganese superoxide dismutase
MPO	Myeloperoxidase
NaOH	Sodium hydroxide
NE	Norepinephrine
NLRP3	NLR family, pyrin domain-containing 3
NO	Nitric oxide
NF- κ B	Nuclear factor kappa B
OD	Optical density
OFT	Open field test
OPT	O-phthalaldehyde
PBS	Phosphate buffered saline
PD	Parkinson disease
p-PI3K	phosphorylated-Phosphatidylinositol3-kinase
PKA	protein kinase A
PKC	protein kinase C
PFC	Prefrontal cortex
P-gp	Permeability glycoprotein
ROS	Reactive oxygen species
RIPA	Radio immunoprecipitation assay

List of abbreviations

SAXA	Saxagliptin
SAD	Seasonal affective disorder
SDS	The severity of dependence scale
SNRIs	Serotonin Norepinephrine Reuptake Inhibitors
SPT	Sucrose preference test
SSRIs	Selective Serotonin Reuptake Inhibitors
SDS	Sodium dodecyl sulphate
SDS-PAGE	sodium dodecyl sulfate polyacrylamide gel electrophoresis
SGOT	Serum glutamic oxaloacetic transaminase
TBARS	Thiobarbituric acid reactive substances
TCA	Trichloroacetic acid
TCAs	Tricyclic Antidepressants
TMB	Tetramethylbenzidine
TNF- α	Tumor necrosis factor-alpha
TBS	Tris-buffered saline
TrkB	Tyrosine kinase receptor B
WHO	World Health Organization
Zn ⁺²	Zinc ion

List of Tables

Table no.	Title	Page no.
I	The stressors applied for 14 days in the chronic unpredictable mild stress model.	49, 50
1	The effect of SAXA on the behavioral changes that occurred in the open field test in the CUMS-subjected rats.	106
2	The effect of SAXA on the behavioral changes that occurred in the forced swimming test in the CUMS-subjected rats.	109
3	The effect of SAXA on the behavioral changes that occurred in the sucrose preference test in the CUMS-subjected rats.	112
4	A semi-quantitative analysis of different treatments on histological structure of different brain areas in rats exposed to CUMS.	118
5	The effect of saxagliptin (0.5 mg/kg) on the brain monoamines contents in the CUMS-subjected rats.	120
6	The effect of saxagliptin (0.5 mg/kg; p.o) on the brain oxidative stress biomarkers glutathione and malondialdehyde in the CUMS-subjected rats	123
7	The effect of saxagliptin (0.5 mg/kg) on the brain inflammatory markers, tumor necrosis factor-alpha, nuclear factor kappa B, and inducible nitric oxide synthase in the CUMS-subjected rats.	127
8	The effect of saxagliptin (0.5 mg/kg) on the brain caspase-3 level in the CUMS-subjected rats.	131
9	The effect of saxagliptin (0.5 mg/kg) on the brain-derived neurotrophic factor contents in the CUMS-subjected rats.	134
10	The effect of saxagliptin (0.5 mg/kg) on the brain glucagon like peptide-1 and glucose-dependent insulinotropic peptide contents in the CUMS-subjected rats.	137
11	The effect of saxagliptin (0.5 mg/kg) on the brain phosphorylated-protein kinase B and phosphorylated-phosphatidylinositol3-kinase contents in the CUMS-subjected rats	141

List of Figures

Figure no.	Title	Page
i	Areas of the brain implicated in the major depressive disorder (MDD).	7
ii	Bi-directional connections between the stress, the brain and inflammatory cytokines. HPA, hypothalamic–pituitary–adrenal axis; SNS, sympathetic nervous system.	10
iii	A simplified model outlining the opposing roles of stress and antidepressant therapy on hippocampal BDNF expression, hippocampal function, and mood	14
iv	Mechanism of action of tricyclic antidepressant (TCAs).	16
v	Mechanism of action of SSRIs inhibitor.	17
vi	A diagram depicting the learned helplessness screening/avoidance test.	20
vii	Effect of chronic stress on the corticosteroids, neurotrophic factors, pro-inflammatory cytokines and the oxidative stress network.	23
viii	The Social Defeat Stress model.	24
ix	Chronic restraint stress model.	25
x	Mechanism of action for GLP-1, GIP analogues and DPP4 inhibitors in controlling type 2 diabetes mellitus.	29
xi	The chemical structure of Saxagliptin.	32
xii	The mechanism of action of Saxagliptin.	32
xiii	Diagrammatic scheme for animal groups for studying the mechanisms underlying of the potential protective dose of saxagliptin in the CUMS subjected rat.	42
xiv	Open Field Test Apparatus.	51
xv	Forced Swimming Test Apparatus.	53
xvi	5-Hydroxytryptamine standard curve.	62
xvii	Norepinephrine standard curve.	64

List of figures

xviii	Dopamine standard curve.	65
xix	Standard curve of tumor necrosis factor-alpha.	74
xx	Standard curve of nuclear factor kappa B.	77
xxi	Standard curve of inducible nitric oxide synthase.	80
xxii	Standard curve of caspase-3.	83
xxiii	Standard curve of brain-derived neurotrophic factor.	88
xxiv	Standard curve of glucagon like peptide-1.	92
xxv	Standard curve of glucose-dependent insulinotropic peptide	96
1	The effect of saxagliptin (0.5, 1, 2 mg/kg; p.o) on the behavioral tests; Latency (A), Ambulation frequency (B), Rearing Frequency (C), Grooming time (D), Grooming frequency (E) in the rats subjected to the chronic unpredictable mild stress.	107
2	The effect of saxagliptin (0.5, 1, 2 mg/kg; p.o) on the behavioral tests; Struggling time (A), Immobility time (B) in the rats subjected to the chronic unpredictable mild stress.	110
3	The effect of saxagliptin (0.5, 1, 2 mg/kg; p.o) on the behavioral test; percentage of sucrose intake in the rats subjected to the chronic unpredictable mild stress.	113
4A	The effect of saxagliptin (0.5, 1, 2 mg/kg; p.o) on the histological structures in the brain cortex of chronic unpredictable mild stress-subjected rats.	114
4B	The effect of saxagliptin (0.5, 1, 2 mg/kg; p.o) on the histological structures in the brain subiculum of chronic unpredictable mild stress-subjected rats.	115
4C	The effect of saxagliptin (0.5, 1, 2 mg/kg; p.o) on the histological structures in the brain fascia dentate & hilus of chronic unpredictable mild stress-subjected rats.	116
4D	The effect of saxagliptin (0.5, 1, 2 mg/kg; p.o) on the histological structures in the brain striatum of chronic unpredictable mild stress-subjected rats.	117

List of figures

5	The effect of saxagliptin (0.5 mg/kg; p.o) on the monoamines contents, Serotonin, Norepinephrine, and Dopamine, in the CUMS-subjected rats.	121
6	The effect of saxagliptin (0.5 mg/kg; p.o) on the glutathione and malondialdehyde brain levels in the CUMS-subjected rats.	124
7	The effect of saxagliptin (0.5 mg/kg; p.o) on the inflammatory markers, tumor necrosis factor-alpha, nuclear factor kappa B, and inducible nitric oxide synthase, in the CUMS-subjected rats.	128
8	The effect of saxagliptin (0.5 mg/kg; p.o) on the apoptotic marker caspase-3 level in the CUMS-subjected rats.	132
9	The effect of saxagliptin (0.5 mg/kg; p.o) on the brain-derived neurotrophic factor levels in the CUMS-subjected rats.	135
10	The effect of saxagliptin (0.5 mg/kg; p.o) on the glucagon like peptide-1 and glucose-dependent insulinotropic peptide brain levels in the CUMS-subjected rats.	138
11	The effect of saxagliptin (0.5 mg/kg; p.o) on the brain phosphorylated-protein kinase B and phosphorylated-Phosphatidylinositol3-kinase expressions in the CUMS-subjected rats.	142

Abstract

Abstract

Depression is recognized to be a worldwide, devastating mental illness, giving rise to poor quality of life and huge economic wastage. It distinguishes by many symptoms; such as persistent depressed mood, loss of pleasure, reduced energy, low self-assuredness, alterations in appetite, and poor concentration. Chronic exposure to stressful life events has been found to be involved in the etiology of neuropsychiatric diseases; such as depression. For that reasons, rats were revealed to an experimental model of chronic unpredictable mild stress (CUMS) model for 14 days. Diverse mild and unpredictable stressors were administered for 14 days in random times with the oral administration of saxagliptin (SAXA) (0.5, 1 and 2 mg/kg) to the treated rat groups.

Saxagliptin which is a member of dipeptidyl peptidase-4 (DPP-4) inhibitors class, has been identified to elevate glucagon-like peptide-1 (GLP-1) level. The emergence of pharmacological agents; such as DPP-4 inhibitors is considered as an important rival in modifying neurodegenerative diseases as Alzheimer's and Parkinson's diseases in the preclinical studies. Accordingly, in the present study, SAXA is utilized to investigate its potential neuroprotective and antidepressant effect in an experimental model of chronic unpredictable mild stress (CUMS) in rats. The effect of SAXA is mostly linked to GLP-1/PI3K/AKT signaling pathway which upon its activation reportedly enhanced cellular survival, reversed neuronal damage and oxidative stress. It also is recognized by its potent anti-oxidant, anti-inflammatory, anti-apoptotic, and neuro-protective activities. SAXA treatment showed a significant elevation in the ambulation frequency, rearing score, grooming time and frequency in open field test (OFT). Additionally, the administration of SAXA displayed a significant increase in struggling time as well as a significant decrease in the immobility time in forced swimming test (FST). Moreover, the sucrose intake in sucrose preference test (SPT) was significantly enhanced in SAXA group. Saxagliptin treatment reversed the CUMS-induced changes in the

Abstract

histopathological examination. Furthermore, it prohibited the CUMS-induced decrease in the monoamines levels and the brain derived neurotrophic factor (BDNF). Contrarily, it decreased the inflammatory, apoptotic and oxidative stress markers. In addition, SAXA treatment elevated the incretin hormones, glucagon like peptide-1 (GLP-1) and glucose-dependent insulintropic peptide (GIP), which are associated with the protein kinase B (AKT)/ phosphatidylinositol3-kinase (PI3K) pathway activation. . In conclusion, these findings revealed that SAXA may show antidepressant activity.

Keywords: Saxagliptin; Chronic unpredictable mild stress; Inflammation; Oxidative stress; glucagon like peptide-1; glucose-dependent insulintropic peptide